KDR and anemia: Furthermore, lenvatinib had stronger signals for anemia (ROR 15.6, 95%CI [6.2–39.0], n = 5), febrile neutropenia (ROR 24.2, 95%CI [11.9–49.2], n = 9) and neutropenia (ROR 8.3, 95%CI [3.0–22.9], n = 4) than the other VEGFR-TKI.